Clinical Trial Update: Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks [Phase 3]

View source ↗

Summary

Phase 3 trial update examining correlation of serum adalimumab levels between 40 mg weekly vs 80 mg every two weeks in inflammatory bowel diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Hospital Universitario La Paz | Conditions: Inflammatory Bowel Diseases | Phase 3 | Status: UNKNOWN